Ac­qui­si­tion talks on­go­ing for Swedish rare dis­ease biotech Egetis, shares up al­most 40%

Shares of the Swe­den-based rare dis­ease biotech Egetis Ther­a­peu­tics sky­rock­et­ed on Thurs­day af­ter­noon as the com­pa­ny said it’s en­gaged in “on­go­ing dis­cus­sion” with ex­ter­nal par­ties …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER